03-Jul-2023 | Zion Market Research
The global Chinese hamster ovary cells (CHO) market size was worth around USD 243.61 million in 2022 and is predicted to grow to around USD 379.51 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.70% between 2023 and 2030.
Chinese hamster ovary cells are derived from the ovary cells of Chinese hamsters. They have wide applications in the biotechnology segment and are used for the production of biopharmaceuticals. CHO cells are mammalian cells and tend to offer several advantages for the production of therapeutic molecules and complex proteins. The application of CHO cells is growing as they are capable of proper protein folding, post-translational modifications such as glycosylation, and high-level expression of recombinant proteins. Such attributes have resulted in CHO cells being used extensively for producing biologics, including monoclonal antibodies, hormones, enzymes, and cytokines. The Chinese hamster ovary cells industry deals with the economic aspects of CHO cell production and its final application.
This review is based on a report by Zion Market Research, titled "Chinese Hamster Ovary Cells (CHO) Market By Application (Clotting Factors, Monoclonal Antibodies, Hormones, Cytokines, Fc-Fusion Protein, Enzymes, And Others), By Product (CHO-DG44, CHO-K1, CHO-S, CHO-DXB1, And Others), By End-User (Contract Development & Manufacturing Organization, Biopharmaceutical Companies, Academic Institutes & Research, Biotech Companies, Clinical Research Organizations, And Others), By System (Metabolic Selection System And Antibiotic Selection System), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030"- Report at https://www.zionmarketresearch.com/report/chinese-hamster-ovary-cells-cho-market
The global Chinese hamster ovary cells (CHO) market is projected to the growing demand for quality patient care as the healthcare industry worldwide is under tremendous pressure with the growing number of patients and the lack of sufficient effective medications or therapies for treating a large number of critical conditions such as autoimmune diseases, cancer, and others. CHO cells are preferred as they have proven to be highly efficient in expressing and producing recombinant proteins as they possess the necessary machinery for correct protein folding, post-translational modifications, and assembly. These factors allow them to be used extensively for the production of complex therapeutic proteins.
Over the years, CHO cells have been studied extensively and after decades of search, they have reached a high level of optimization. The presence of longer track records in terms of exhaustive research & development (R&D) has provided researchers with a deep understanding of CHO cell physiology, genetics, and culture conditions. The availability of a robust CHO cell line also works in favor of the Chinese hamster ovary cells industry. In addition to this, growing demand for biosimilars, technological advancements, and higher regulatory acceptance further adds to the revenue generated in the sector.
The global Chinese hamster ovary cells market may face growth restrictions owing to concerns over intellectual property rights as the use of CHO cells in biopharmaceutical production is generally subject to intellectual property restrictions and licensing agreements. Certain cell lines or associated technologies may not be accessible to all owing to patents which cause an increase in the cost for companies seeking to use them. Moreover, the complications related to the regulation of CHO cell use can be tricky, especially during international dealings. The presence of alternative expression systems such as yeast, bacteria, and plant-based systems are also used extensively apart from CHO cells which adds to limited growth in the CHO cell industry.
The rising efforts toward higher production of biosimilars may provide growth opportunities while the scaling up of CHO cell-based biopharmaceutical products may challenge market expansion.
The global Chinese hamster ovary cells (CHO) market is segmented based on application, product, end-user, system, and region.
Based on application, the global market segments are clotting factors, monoclonal antibodies, hormones, cytokines, Fc-fusion protein, enzymes, and others.
Based on product, the Chinese hamster ovary cells industry is segmented into CHO-DG44, CHO-K1, CHO-S, CHO-DXB1, and others. During 2022, CHO-KI also known as Chinese Hamster Ovary-K1 remained the dominating product type. These cells exhibit robust growth characteristics along with greater production capacity in terms of high yields of recombinant proteins. Although other product forms also have specific applications, the extensive characterization and optimization of CHO-K1 for growth and protein expression have resulted in the development of an established track record, availability of documentation & protocols, and compatibility with existing manufacturing processes which cannot be found with other forms. There are currently around 41 US Food and Drugs Administration (FDA) approved biosimilars on the market.
Based on end-user, the global market divisions are contract development & manufacturing organization, biopharmaceutical companies, academic institute & research, biotech companies, clinical research organization, and others.
Based on the system, the Chinese hamster ovary cells industry is segmented into metabolic selection system and antibiotic selection system. The most adopted system is the antibiotic selection system when compared to the metabolic selection system. It involves the use of antibiotics such as G418 (geneticin) or puromycin. They help to select CHO cells that have incorporated a selectable marker gene, typically a resistance gene. The system is widely adopted due to its simplicity, convenience, and efficiency. It is an effective method for the selection of transfected cells quickly and effectively. However, in this system, cell culture systems should be carefully considered and optimized to minimize potential impacts on cell health and product quality. In 2020, the production cost of mAbs using CHO cells was around $50–100 per gram.
The global Chinese hamster ovary cells (CHO) market is expected to witness the highest growth in North America led by the presence of major biopharmaceutical companies, contract development & manufacturing organizations (CDMOs), and research institutions that are involved in the extensive use of CHO cell for various medical purposes ranging from research to development of novel medicines. The United States is known as the hub for biotechnology innovation.
In Europe, high CAGR may be observed in countries such as Germany, Switzerland, the United Kingdom, and Ireland due to the growing focus of the regional companies toward CHO cell-based production. Presently, European pharmaceutical companies are involved in the production of several types of biologic drugs, including monoclonal antibodies, hormones, and enzymes that use CHO cells.
The global Chinese hamster ovary cells (CHO) market is led by players like:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651